Pharmacy
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • HOME

      RINVOQ

      HUMIRA

      SKYRIZI

      EDUCATION

      SERVICES

      CONTACT

      AbbVie Care logo

      AbbVie Care is your trusted partner complementing the care of HUMIRA (adalimumab) and SKYRIZI (risankizumab) patients

      Patients enrolled in AbbVie Care will have access to a range of resources including nurse consultations (virtual or in person), injection support, sharps containers and travel solutions. ​

      Enrolment is simple. Patients can:

      Scan the QR code on the HUMIRA pack

      Visit abbviecare.com.au

      QR code

      Example QR code.

      OR
      OR


      Use access code:
      my journey
      or
      the last 4 digits of the barcode on your pack

      Patient Support barcode diagram

      For patients who are unable to self-enrol:

      Download the PDF enrolment form ➜

      AbbVie Care provides patients access to:

      HUMIRA Welcome Kit thumbnail
      HUMIRA AbbVie Care Welcome Kit

      VIEW CONTENTS ➜

      SKYRIZI Welcome Kit thumbnail
      SKYRIZI AbbVie Care Welcome Kit

      VIEW CONTENTS ➜

      Sharps and Travel Solutions thumbnail
      AbbVie Care Sharps and Travel Solutions

      VIEW CONTENTS ➜

      In Clinic Kit Thumbnail
      HUMIRA AbbVie Care In Clinic Kit

      VIEW CONTENTS ➜

      Contact a rep
      Contact a rep

      More for you

      AbbVie Care thumbnail
      AbbVie Care resources
      Skyrizi resources
      SKYRIZI resources
      Rinvoq resources
      RINVOQ resources

      WARNING: Based on the results from a post-marketing safety study of another JAK inhibitor, RINVOQ should only be used if no suitable treatment alternatives are available in patients:
      • With history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long time smokers).
      • With malignancy risk factors (e.g. current malignancy or history of malignancy).
      • Who are 65 years of age and older.

      Refer to Product Information.

      PBS Information

      RINVOQ: Authority required. Refer to PBS Schedule for full authority information.

      HUMIRA: Authority required. Refer to PBS Schedule for full authority information. This product is not listed on the PBS for the treatment of enthesitis-related arthritis or paediatric psoriasis.

      SKYRIZI: Authority required for the treatment of adults with severe plaque psoriasis. SKYRIZI is not listed on the PBS for the treatment of psoriatic arthritis. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      RINVOQ PI

      HUMIRA PI

      SKYRIZI PI

      AU-ABBV-220264. May 2024